Asymmetrical dimethylarginine level in atrial fibrillation

Cengel A., ŞAHİNARSLAN A., BİBEROĞLU G., Hasanoglu A., Tavil Y., Tulmac M., ...More

ACTA CARDIOLOGICA, vol.63, no.1, pp.33-37, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 63 Issue: 1
  • Publication Date: 2008
  • Doi Number: 10.2143/ac.63.1.2025329
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.33-37
  • Keywords: ADMA, thrombosis, endothelial dysfunction, COAGULATION, INHIBITOR
  • Gazi University Affiliated: Yes


Objective - Atrial fibrillation (AF) is known to be related with increased risk of thromboembolic events. Asymmetrical dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS), can cause endothelial dysfunction by decreasing nitric oxide (NO) and lead to increased risk of thrombosis. In the present study our aim was to compare plasma levels of ADMA in patients with acute onset (< 24 hours) and chronic AF (> I year) to determine the risk of thrombosis.